Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 30331.13% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 45.95M.
Subavaliada
O PE mais recente da empresa é -42.80, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 47.75M ações, uma redução de 3.15% em relação ao trimestre anterior.
Mantido por John Hussman
O Super Investidor John Hussman possui 84.59K ações desta empresa.